$OKLO

Cochran Caroline sold $4.1M of OKLO (indirect holdings)

Cochran Caroline (Co-Founder, COO) sold 60,000 indirectly-held shares of Oklo Inc. (OKLO) at $68.29 ($4.10M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cochran Caroline
Published Jun 2, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

The disclosure can influence short-term sentiment, but 10b5-1 plans are designed to reduce timing-based inference about private information.

02

Market read

A disclosed insider sale can create minor negative read-through, but the 10b5-1 pre-arrangement lowers the probability of a new fundamental development.

03

What to watch

Watch for whether multiple insiders are selling around the same time or whether the sale size is unusually large relative to prior Form 4 activity; the article provides only this single transaction.

Relevance 6/10Novelty 6/10Timing: After-hours disclosure of a 6/1 insider sale filing on 6/2

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by an officer/director/10% owner under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder/COO and 10% owner sold 60,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited immediate impact expected; any reaction likely fades unless accompanied by other negative catalysts.

Evidence & confidence

The filing is a routine insider transaction with an explicit pre-arranged 10b5-1 plan, reducing the probability it reflects new private information.

Market effects

Minimal; this is company-specific insider activity without stated operational/financing changes.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may be largely mechanical and not a bearish signal; traders may fade any knee-jerk selling.

Key entities

  • Oklo Inc.

    Subject of the insider transaction disclosure (Form 4).

  • Cochran Caroline

    Co-founder, COO, officer/director, and 10% owner who sold shares.

Related articles

$OKLOMedAI 8/10

Oklo’s (OKLO) Groves Reactor Hits Criticality In Under A Year

Oklo Inc. (NYSE:OKLO) said its Groves Isotope Test Reactor in Lockhart, Texas, reached first criticality on Aug. 6, less than a year after groundbreaking. The company said it is the first Reactor Pilot Program project to reach criticality on private land from a greenfield site. Oklo reported a quarterly net loss of $81.6M and raised 2026 cash flow and capex guidance.

$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.